← All trials
NCT04351685
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 10, 2020
- Primary completion
- Jul 10, 2023
- Completion date
- Jun 10, 2025
- First posted
- Apr 17, 2020
- Last posted
- Apr 17, 2020
- Enrollment
- 6940
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Serum Institute of India Pvt. Ltd.Lead sponsor
- Serum Institute of India Pvt. Ltd.Study director
- Vakzine Projekt Management GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.